- Home
- FBRX vs MHN Comparison
FBRX vs MHN Comparison
Compare FBRX & MHN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$31.38
Company Overview
Basic Information| Metric | FBRX | MHN |
|---|---|---|
| Founded | N/A | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 367.4M | 311.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | FBRX | MHN |
|---|---|---|
| Price | $31.38 | $10.25 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $67.00 | N/A |
| AVG Volume (30 Days) | ★ 176.8K | 59.2K |
| Earning Date | 11-14-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.17% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.90 | $8.69 |
| 52 Week High | $35.46 | $10.81 |
Technical Indicators
Market Signals| Indicator | FBRX | MHN |
|---|---|---|
| Relative Strength Index (RSI) | 60.77 | 42.14 |
| Support Level | $29.79 | $10.22 |
| Resistance Level | $33.58 | $10.40 |
| Average True Range (ATR) | 3.49 | 0.07 |
| MACD | 0.13 | -0.01 |
| Stochastic Oscillator | 70.81 | 4.55 |
Price Performance
Historical Comparison FBRX
MHN
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).
About MHN Blackrock MuniHoldings New York Quality Fund Inc.
BLACKROCK MUNIHOLDINGS NEW YORK QUALITY FUND, INC. is a closed-ended management investment company. The fund's investment objective is to provide shareholders with current income exempt from federal income tax and New York State and New York City personal income taxes.